Morgan Stanley analyst Tejas Savant maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and maintains the target price at $265.
According to TipRanks data, the analyst has a success rate of 37.5% and a total average return of -6.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
Iqvia experienced a 'modest beat' in Q3 due to a performance that surpassed expectations in the TAS segment. However, this success is being overshadowed by challenges in the R&DS sector, which include a significant cancellation and the postponement of two major trials to 2025. Despite these headwinds, the perceived risk/reward is deemed favorable following the stock's recent decline.
The market appears stable, yet the company is facing challenges with bookings due to delays and drug failures rather than significant effects from pipeline rationalization.
The company has encountered a challenging industry operating environment. Comments from the company indicate that pharma portfolio reprioritizations related to the IRA may be concluding, and the company seems to be gaining from the pharmaceutical industry's vendor consolidation trend.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Tejas Savant維持$艾昆緯 (IQV.US)$買入評級，維持目標價265美元。
根據TipRanks數據顯示，該分析師近一年總勝率為37.5%，總平均回報率為-6.3%。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
愛普生在第三季度經歷了一次'小幅超越'，這是由於在TAS板塊表現超出預期。然而，這一成功被在研發生產板塊中的挑戰所遮蓋，其中包括一次重大取消和兩項重大試驗推遲至2025年。儘管面臨這些阻力，但由於股價最近的下跌，風險/回報比被認爲是有利的。
市場看起來是穩定的，但公司由於延遲和藥品失敗而面臨預訂挑戰，而不是因爲管線精簡的顯著影響。
公司遇到了具有挑戰性的行業板塊營運環境。公司的評論表明，與取得的 IRA 相關的藥品組合重置可能正在結束，公司似乎正在從藥品行業的供應商整合趨勢中獲益。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
